摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Acetyl-3-methyl-1,2,3,4-tetrahydro-iso-chinolin | 19603-75-9

中文名称
——
中文别名
——
英文名称
2-Acetyl-3-methyl-1,2,3,4-tetrahydro-iso-chinolin
英文别名
2-acetyl-3-methyl-1,2,3,4-tetrahydro-isoquinoline;1-(3-methyl-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
2-Acetyl-3-methyl-1,2,3,4-tetrahydro-iso-chinolin化学式
CAS
19603-75-9
化学式
C12H15NO
mdl
——
分子量
189.257
InChiKey
NJYOZPPQGIEZKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • Benzolactam compounds as protein kinase inhibitors
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:US10457669B2
    公开(公告)日:2019-10-29
    The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
    本发明提供了一种式 (0) 的化合物: 或其药学上可接受的盐、N-氧化物或同系物;其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N; R1 选自 -(Alk1)t-Cyc1;其中 t 为 0 或 1; 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个原子取代的 C1-3 烃基; R3 是氢或基团 L1-R7; R4 选自氢、甲氧基和任选被取代的 C1-3 烷基;以及 R4a 选自氢和 C1-3 烷基; 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义; 只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂,可用于治疗 ERK1/2 介导的疾病。因此,这些化合物可用于治疗,特别是治疗癌症。
  • PROLYL ENDOPEPTIDASE PROBES
    申请人:SRI International
    公开号:EP2616808B1
    公开(公告)日:2015-02-25
  • ISOPRENYL COMPOUNDS AND METHODS THEREOF
    申请人:Signum Biosciences, Inc.
    公开号:EP3330252B1
    公开(公告)日:2020-02-12
  • Prolyl Endopeptidase Probes
    申请人:Galande Amit K.
    公开号:US20120065103A1
    公开(公告)日:2012-03-15
    Prolyl endopeptidase (PE) activity in lung samples is detected by contacting the lung sample with a probe comprising a —P—X— (or —X—P—, —P—X—P—) PE recognition site, wherein P is a prolyl bioisostere, X is a residue that is not a prolyl bioisostere or is a prolyl bioisostere flanked on each side by a residue that is not a prolyl bioisostere, and “-” is an amide bond, under conditions wherein PE activity of the sample specifically hydrolyzes an amide bond of the recognition site to generate an optical signal; and (b) detecting the signal.
  • Isoprenyl Compounds and Methods Thereof
    申请人:SIGNUM BIOSCIENCES, INC.
    公开号:US20160361283A1
    公开(公告)日:2016-12-15
    Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
查看更多